Silverback Therapeutics (NASDAQ:SBTX) Trading Up 6.3% - What's Next?

Key Points

• Silverback Therapeutics' stock increased by 6.3%, with shares reaching a high of $10.78 during trading on Tuesday.
• The company experienced a significant surge in trading volume, with approximately 5 million shares exchanged, a rise of 1,403% from its average daily volume.
• Silverback Therapeutics specializes in developing tissue-targeted therapeutics for chronic viral infections and cancer, including the treatment of hepatitis B virus with their product SBT8230.

Silverback Therapeutics, Inc. (NASDAQ:SBTX - )'s stock price was up 6.3% on Tuesday . The company traded as high as $10.78 and last traded at $10.70. Approximately 5,079,647 shares were traded during trading, an increase of 1,403% from the average daily volume of 337,931 shares. The stock had previously closed at $10.07.

Silverback Therapeutics Price Performance

The business's fifty day moving average price is $15.75 and its 200-day moving average price is $14.35. The stock has a market capitalization of $385.82 million, a PE ratio of -4.42 and a beta of 0.60.

About Silverback Therapeutics

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.